ClinicalTrials.gg
CompletedNCT03519971Updated Jul 14, 2026Results posted

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

A Phase 3 interventional study of Durvalumab and Placebo in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 86 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
19th of 94
328 · median 74
Started
2018
with 7 others
Phase 3
17 of 94
3 open now
Registered
31st of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment, is one of 8 that started in 2018, is one of 17 in phase 3, and was the 31st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC] CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Locally Advanced, Unresectable NSCLC, Carcinoma, NSCLC
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal inclusion criteria :

  • Subjects with - or cytologically-documented NSCLC
  • Locally advanced, unresectable (Stage III) NSCLC
  • World Health Organisation (WHO) performance status 0-1
  • At least one , not previously irradiated
  • Must have a of at least 12 weeks at randomization

Principal exclusion criteria :

  • Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, agents, chemotherapy, Durvalumab and mAbs.
  • Prior exposure to immune-mediated therapy, including but not limited to, other anti , anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines.
  • History of allogeneic organ transplantation
  • Active or prior documented or inflammatory disorders
  • Uncontrolled intercurrent illness
  • History of another primary / / active primary immunodeficiency
  • Active infection including tuberculosis, , , or
  • Mixed small cell and NSCLC histology
  • Any medical to treatment with platinum-based doublet chemotherapy as listed in the local labelling
  • Known allergy or to any of the IPs or any of the IP .
  • Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    Arm 1: Durvalumab + platinum-based chemotherapy and radiation

    Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy. All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy: * cisplatin/etoposide * carboplatin/paclitaxel * pemetrexed/cisplatin * pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment.

    Drug: Durvalumab · Drug: Cisplatin/ Etoposide · Drug: Carboplatin/ Paclitaxel · Drug: Pemetrexed/ Cisplatin · Drug: Pemetrexed/ Carboplatin · Radiation: Radiation

  • Placebo comparator
    Arm 2: Placebo + platinum-based chemotherapy and radiation

    Placebo in concurrence with platinum-based chemo-radiation therapy. All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy: * cisplatin/etoposide * carboplatin/paclitaxel * pemetrexed/cisplatin * pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment.

    Other: Placebo · Drug: Cisplatin/ Etoposide · Drug: Carboplatin/ Paclitaxel · Drug: Pemetrexed/ Cisplatin · Drug: Pemetrexed/ Carboplatin · Radiation: Radiation

Interventions

  • Durvalumab IV (intravenous infusion)

    Also known as: MEDI4736

  • OtherPlacebo

    Placebo IV (intravenous infusion)

  • DrugCisplatin/ Etoposide

    Cisplatin/ Etoposide, as per standard of care

  • DrugCarboplatin/ Paclitaxel

    Carboplatin /Paclitaxel, as per standard of care

  • DrugPemetrexed/ Cisplatin

    Drug pages: Pemetrexed · Cisplatin

    Pemetrexed / Cisplatin, as per standard of care

  • DrugPemetrexed/ Carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Pemetrexed / Carboplatin , as per standard of care

  • RadiationRadiation

    5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).

Secondary outcomes

  1. Objective Response Rate (ORR)

    The ORR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of complete response (CR) or partial response (PR) based on all participants in the FAS. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions.

    Time frame: Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).

  2. Overall Survival (OS)

    The OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From screening until confirmed PD, assessed up to the DCO date (a maximum of approximately 1988 days).

  3. Percentage of Participants Alive at 24 Months From Randomization (OS24)

    The OS24 was defined as the Kaplan-Meier estimate of OS at 24 months. Median OS24 was calculated using the Kaplan-Meier technique.

    Time frame: Month 24

  4. Complete Response Rate (CRR)

    The CRR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of CR. The CR was defined as disappearance of all target lesions since baseline.

    Time frame: Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).

  5. Duration of Response (DoR)

    The DoR per RECIST 1.1 using BICR was defined as the time from the date of first documented response (which was subsequently confirmed) until the first date of documented progression or death in the absence of PD. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions. The DoR was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).

  6. Disease Control Rate (DCR)

    The DCR at 24 weeks per RECIST 1.1 using BICR was defined as the percentage of participants who had a best objective response of CR or PR in the first 25 weeks (to allow for late assessment within the assessment window) or who had stable disease for \>= 23 weeks after randomization (to allow for an early assessment within the ± 1 week assessment window).

    Time frame: Week 24

  7. Time to Death or Distant Metastasis (TTDM)

    The TTDM per RECIST 1.1 using BICR was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that was outside the radiation field according to RECIST 1.1 or proven by biopsy.

    Time frame: Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).

  8. Time From Randomization to Second Progression (PFS2)

    The PFS2 was defined as the time from the date of randomization to the earliest of the progression event (subsequent to that used for the primary variable PFS per Investigator assessment) or death. The date of the second progression was recorded by the Investigator and defined according to local standard clinical practice and could have involved any of objective radiological, symptomatic progression, or death. Median PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).

  9. Serum Concentration of Durvalumab

    Blood samples were collected to determine the concentration of durvalumab.

    Time frame: End of infusion on Week 0, pre-infusion on Weeks 4 and 12, and Month 3 follow-up

  10. Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

    Blood samples were collected to determine the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence was defined as the number of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as either treatment-induced (post-baseline ADA positive only) or treatment-boosted ADA (baseline positive ADA titer that was boosted to \>= 4-fold during the study period). Treatment-induced ADA was defined as ADA positive only post-baseline and not detected at baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive assessments with at least 16 weeks between the first and last positive assessment, or ADA positive at the last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment without fulfilling the conditions for persistently positive.

    Time frame: Pre-dose on Day 1 of Cycles 1, 2 and 4

  11. Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Average Over 12 Months

    Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a total score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status scale with higher scores on the global health status/quality of life (QoL) and functioning scales representing better health status/function, but higher scores on symptom scales/items representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as a change from baseline of \>=10.

    Time frame: At screening, 2, 4, 6, 8, 12, 16, and 20 weeks after randomization, then every 8 weeks ±1 week up to 52 weeks, and then every 12 weeks ±1 week thereafter until PFS2. Assessed up to 12 months.

  12. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is the development of any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of study treatment were those with action taken was 'Drug Permanently Discontinued' for any study treatment.

    Time frame: From time of signature of informed consent up to 90 days after last dose of study treatment or up to the date of initiation of the first subsequent therapy, whichever occurs first, approximately 1988 days.

07

Results

Posted Jan 7, 2025

Participant flow

This Phase III double-blind, placebo-controlled study was conducted in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) at 87 study centers in North and South America, Europe, and Asia Pacific. The results are reported for analysis with assessment until data cut-off (DCO) date of 07 September 2023.

Participant flow — Overall Study
MilestoneDurvalumab + SoC CRTPlacebo + SoC CRT
Started219109
Received treatment218109
Completed00
Not completed219109
Withdrew: Death14269
Withdrew: Lost to follow-up01
Withdrew: Ongoing treatment and in follow-up at data cut off7337
Withdrew: Withdrawal by subject32
Withdrew: Other10

Outcome measures

PrimaryProgression-Free Survival (PFS)

The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsDurvalumab + SoC CRTPlacebo + SoC CRT
Progression-Free Survival (PFS)13.8 (9.5 to 16.9)9.4 (7.5 to 16.6)
Statistical analysis
  • Durvalumab + SoC CRT vs Placebo + SoC CRT · Log Rank · p = 0.247 · Hazard ratio (hr): 0.85 · 95% CI 0.647 to 1.123The analysis was performed using the stratified log-rank test, adjusting for age (\< 65 vs. \>= 65 years) and stage (IIIA vs. IIIB/C).
SecondaryObjective Response Rate (ORR)

The ORR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of complete response (CR) or partial response (PR) based on all participants in the FAS. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions.

Time frame:
Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsDurvalumab + SoC CRTPlacebo + SoC CRT
Objective Response Rate (ORR)60.7 (53.9 to 67.2)60.6 (50.7 to 69.8)
Statistical analysis
  • Durvalumab + SoC CRT vs Placebo + SoC CRT · Cochran-Mantel-Haenszel · p = 0.976 · Difference in percentages: 0.2 · 99.50% CI -15.2 to 16.3The CIs for difference in percentages were estimated using Miettinen and Nurminen's method.
SecondaryOverall Survival (OS)

The OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From screening until confirmed PD, assessed up to the DCO date (a maximum of approximately 1988 days).
Reported as:
Median · months
Overall Survival (OS)
monthsDurvalumab + SoC CRTPlacebo + SoC CRT
Overall Survival (OS)36.4 (26.2 to 45.6)29.5 (23.2 to 45.1)
Statistical analysis
  • Durvalumab + SoC CRT vs Placebo + SoC CRT · Log Rank · p = 0.823 · Hazard ratio (hr): 1.03 · 95% CI 0.778 to 1.386The analysis was performed using the stratified log-rank test, adjusting for age (\< 65 vs. \>= 65 years) and stage (IIIA vs. IIIB/C).
SecondaryPercentage of Participants Alive at 24 Months From Randomization (OS24)

The OS24 was defined as the Kaplan-Meier estimate of OS at 24 months. Median OS24 was calculated using the Kaplan-Meier technique.

Time frame:
Month 24
Reported as:
Number · percentage of participants
Percentage of Participants Alive at 24 Months From Randomization (OS24)
percentage of participantsDurvalumab + SoC CRTPlacebo + SoC CRT
Percentage of Participants Alive at 24 Months From Randomization (OS24)58.4 (51.6 to 64.7)59.5 (49.6 to 68.2)
Statistical analysis
  • Durvalumab + SoC CRT vs Placebo + SoC CRT · Log Rank · p = 0.847 · Hazard ratio (hr): 1.04 · 95% CI 0.716 to 1.502The analysis was performed using the stratified log-rank test, adjusting for age (\< 65 vs. \>= 65 years) and stage (IIIA vs. IIIB/C).
SecondaryComplete Response Rate (CRR)

The CRR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of CR. The CR was defined as disappearance of all target lesions since baseline.

Time frame:
Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).
Reported as:
Number · percentage of participants
Complete Response Rate (CRR)
percentage of participantsDurvalumab + SoC CRTPlacebo + SoC CRT
Complete Response Rate (CRR)1.8 (0.5 to 4.6)1.8 (0.2 to 6.5)
Statistical analysis
  • Durvalumab + SoC CRT vs Placebo + SoC CRT · Difference in percentages: 0.0 · 95% CI -4.8 to 3.0The CIs for difference in percentages was calculated using Miettinen and Nurminen's method.
SecondaryDuration of Response (DoR)

The DoR per RECIST 1.1 using BICR was defined as the time from the date of first documented response (which was subsequently confirmed) until the first date of documented progression or death in the absence of PD. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions. The DoR was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).
Reported as:
Median · months
Duration of Response (DoR)
monthsDurvalumab + SoC CRTPlacebo + SoC CRT
Duration of Response (DoR)30.7 (8.8 to NA)18.6 (7.4 to 56.5)
SecondaryDisease Control Rate (DCR)

The DCR at 24 weeks per RECIST 1.1 using BICR was defined as the percentage of participants who had a best objective response of CR or PR in the first 25 weeks (to allow for late assessment within the assessment window) or who had stable disease for \>= 23 weeks after randomization (to allow for an early assessment within the ± 1 week assessment window).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsDurvalumab + SoC CRTPlacebo + SoC CRT
Disease Control Rate (DCR)65.865.1
SecondaryTime to Death or Distant Metastasis (TTDM)

The TTDM per RECIST 1.1 using BICR was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that was outside the radiation field according to RECIST 1.1 or proven by biopsy.

Time frame:
Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).
Reported as:
Median · months
Time to Death or Distant Metastasis (TTDM)
monthsDurvalumab + SoC CRTPlacebo + SoC CRT
Time to Death or Distant Metastasis (TTDM)51.0 (25.0 to NA)46.3 (16.6 to NA)
Statistical analysis
  • Durvalumab + SoC CRT vs Placebo + SoC CRT · Log Rank · p = 0.790 · Hazard ratio (hr): 0.95 · 95% CI 0.649 to 1.413The analysis was performed using the stratified log-rank test, adjusting for age (\< 65 vs. \>= 65 years) and stage (IIIA vs. IIIB/C).
SecondaryTime From Randomization to Second Progression (PFS2)

The PFS2 was defined as the time from the date of randomization to the earliest of the progression event (subsequent to that used for the primary variable PFS per Investigator assessment) or death. The date of the second progression was recorded by the Investigator and defined according to local standard clinical practice and could have involved any of objective radiological, symptomatic progression, or death. Median PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).
Reported as:
Median · months
Time From Randomization to Second Progression (PFS2)
monthsDurvalumab + SoC CRTPlacebo + SoC CRT
Time From Randomization to Second Progression (PFS2)27.8 (21.8 to 35.8)22.0 (16.2 to 28.0)
Statistical analysis
  • Durvalumab + SoC CRT vs Placebo + SoC CRT · Log Rank · p = 0.132 · Hazard ratio (hr): 0.81 · 95% CI 0.614 to 1.071The analysis was performed using the stratified log-rank test, adjusting for age (\< 65 vs. \>= 65 years) and stage (IIIA vs. IIIB/C).
SecondarySerum Concentration of Durvalumab

Blood samples were collected to determine the concentration of durvalumab.

Time frame:
End of infusion on Week 0, pre-infusion on Weeks 4 and 12, and Month 3 follow-up
Reported as:
Geometric mean · microgram per milliliter
Serum Concentration of Durvalumab
microgram per milliliterDurvalumab + SoC CRT
Week 0: End of infusion452.21 ± 78.94
Week 4: Pre-infusion82.02 ± 80.85
Week 12: Pre-infusion123.39 ± 163.20
Month 3 Follow-up15.79 ± 243.41
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

Blood samples were collected to determine the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence was defined as the number of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as either treatment-induced (post-baseline ADA positive only) or treatment-boosted ADA (baseline positive ADA titer that was boosted to \>= 4-fold during the study period). Treatment-induced ADA was defined as ADA positive only post-baseline and not detected at baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive assessments with at least 16 weeks between the first and last positive assessment, or ADA positive at the last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment without fulfilling the conditions for persistently positive.

Time frame:
Pre-dose on Day 1 of Cycles 1, 2 and 4
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
ParticipantsDurvalumab + SoC CRT
ADA positive at any visit (ADA prevalence)20
Treatment-emergent ADA positive (ADA incidence)8
ADA positive at both baseline and post-baseline2
Treatment-induced ADA8
ADA positive at baseline only10
Treatment-boosted ADA0
Persistent positive6
Transient positive4
nAb positive at any visit1
SecondaryChange From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Average Over 12 Months

Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a total score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status scale with higher scores on the global health status/quality of life (QoL) and functioning scales representing better health status/function, but higher scores on symptom scales/items representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as a change from baseline of \>=10.

Time frame:
At screening, 2, 4, 6, 8, 12, 16, and 20 weeks after randomization, then every 8 weeks ±1 week up to 52 weeks, and then every 12 weeks ±1 week thereafter until PFS2. Assessed up to 12 months.
Reported as:
Mean · units on a scale
Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Average Over 12 Months
units on a scaleDurvalumab + SoC CRTPlacebo + SoC CRT
EORTC QLQ-C30: Global health status/QoL-0.5 (-2.3 to 1.4)0.2 (-2.4 to 2.8)
EORTC QLQ-C30: Physical functioning-1.4 (-3.0 to 0.2)-0.8 (-3.1 to 1.4)
EORTC QLQ-C30: Fatigue symptoms1.3 (-0.9 to 3.4)0.3 (-2.8 to 3.3)
EORTC QLQ-C30: Appetite loss symptoms3.0 (0.9 to 5.2)0.3 (-2.7 to 3.3)
EORTC QLQ-LC13: Dyspnoea symptoms1.1 (-1.0 to 3.1)-1.3 (-4.2 to 1.6)
EORTC QLQ-LC13: Cough symptoms-6.1 (-8.6 to -3.6)-6.5 (-10.0 to -2.9)
EORTC QLQ-LC13: Pain in chest symptoms-1.9 (-4.2 to 0.4)-0.8 (-3.9 to 2.4)
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is the development of any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of study treatment were those with action taken was 'Drug Permanently Discontinued' for any study treatment.

Time frame:
From time of signature of informed consent up to 90 days after last dose of study treatment or up to the date of initiation of the first subsequent therapy, whichever occurs first, approximately 1988 days.
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsDurvalumab + SoC CRTPlacebo + SoC CRT
Any AE98.6100.0
Any SAE47.051.9
Any AE leading to discontinuation of treatment34.719.4
Any immune-mediated AE48.928.7

Adverse events

Collected over From time of signature of informed consent up to 90 days after last dose of study treatment or up to the date of initiation of the first subsequent therapy, whichever occurs first, approximately 1988 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab + SoC CRT142/219 (64.8%)103/219 (47%)209/219 (95.4%)
Placebo + SoC CRT69/109 (63.3%)56/108 (51.9%)106/108 (98.1%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventDurvalumab + SoC CRTPlacebo + SoC CRT
PneumoniaInfections and infestations29/21911/108
PneumonitisRespiratory, thoracic and mediastinal disorders13/2195/108
Febrile neutropeniaBlood and lymphatic system disorders6/2196/108
FatigueGeneral disorders2/2195/108
Radiation oesophagitisInjury, poisoning and procedural complications5/2195/108
Pneumonia bacterialInfections and infestations1/2194/108
Radiation pneumonitisInjury, poisoning and procedural complications4/2194/108
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/2193/108
SepsisInfections and infestations6/2191/108
Pyelonephritis acuteInfections and infestations0/2192/108
Most frequent other events
Showing 10 of 53
Most frequent other events
EventDurvalumab + SoC CRTPlacebo + SoC CRT
AnaemiaBlood and lymphatic system disorders90/21940/108
ConstipationGastrointestinal disorders35/21931/108
NeutropeniaBlood and lymphatic system disorders59/21928/108
NauseaGastrointestinal disorders55/21926/108
LeukopeniaBlood and lymphatic system disorders48/21919/108
Decreased appetiteMetabolism and nutrition disorders46/21921/108
CoughRespiratory, thoracic and mediastinal disorders46/21918/108
ThrombocytopeniaBlood and lymphatic system disorders44/21919/108
Radiation oesophagitisInjury, poisoning and procedural complications38/21918/108
LymphopeniaBlood and lymphatic system disorders29/21918/108

Baseline characteristics

The Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Durvalumab + SoC CRTPlacebo + SoC CRTTotal
Mean62.8 ± 8.9662.4 ± 9.5062.6 ± 9.13
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab + SoC CRTPlacebo + SoC CRTTotal
Female532982
Male16680246
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + SoC CRTPlacebo + SoC CRTTotal
White14162203
Black or African American202
Asian6539104
American Indian or Alaska Native7714
Other415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + SoC CRTPlacebo + SoC CRTTotal
Hispanic or Latino332154
Not Hispanic or Latino18688274
08

Study locations

86 sites
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Ribeirão Preto, 14021-636, Brazil
  • Research Site
    Ribeirão Preto, 14048900, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Ostrava, 703 00, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Bangalore, 560068, India
  • Research Site
    Chennai, 600035, India
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Karamsad, 388325, India
  • Research Site
    Mumbai, 400053, India
  • Research Site
    Nashik, 422005, India
  • Research Site
    New Delhi, 110063, India
  • Research Site
    Vadodara, 390007, India
  • Research Site
    Bunkyō City, 113-8603, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Kyoto, 606-8507, Japan
  • Research Site
    Nagoya, 464-8681, Japan
  • Research Site
    Sayama, 589-8511, Japan
  • Research Site
    Sendai, 980-0873, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Guadalajara, 44280, Mexico
  • Research Site
    Mexico City, 0 3100, Mexico
  • Research Site
    Mérida, 97134, Mexico
  • Research Site
    México, 04700, Mexico
  • Research Site
    Orizaba, 94300, Mexico
  • Research Site
    La Libertad, 13013, Peru
  • Research Site
    Lima, 15033, Peru
  • Research Site
    Lima, L27, Peru
  • Research Site
    Lima, LIMA 27, Peru
  • Research Site
    Lima, LIMA 34, Peru
  • Research Site
    Lima, LIMA 41, Peru
  • Research Site
    Cebu City, 6000, Philippines
  • Research Site
    City of Taguig, 1634, Philippines
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Makati, 1229, Philippines
  • Research Site
    Manila, 1015, Philippines
  • Research Site
    Quezon City, Philippines
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Elblag, 02-300, Poland
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Arkhangelsk, 163045, Russia
  • Research Site
    Chelyabinsk, 454087, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 115533, Russia
  • Research Site
    Moscow, 125367, Russia
  • Research Site
    Omsk, 644013, Russia
  • Research Site
    Rostov-on-Don, 344037, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Busan, 48108, South Korea
  • Research Site
    Chungcheongbuk-do, 28644, South Korea
  • Research Site
    Gyeongsangnam-do, 52727, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 6351, South Korea
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10400, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Khon Kaen, 40002, Thailand
  • Research Site
    Mueang, 50200, Thailand
  • Research Site
    Ankara, 06230, Turkey (Türkiye)
  • Research Site
    Ankara, Turkey (Türkiye)
  • Research Site
    Antalya, 07059, Turkey (Türkiye)
  • Research Site
    Diyarbakır, 21280, Turkey (Türkiye)
  • Research Site
    Istanbul, 34030, Turkey (Türkiye)
  • Research Site
    Izmir, 35100, Turkey (Türkiye)
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Hanoi, 10000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Sep 2023, 65 months.

Results were first posted in Jan 2025, 1 year 4 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 65 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
May 9, 2018
StartActual
Mar 29, 2018
Primary completionActual
Sep 7, 2023
CompletionActual
Mar 9, 2026
Results first posted
Jan 7, 2025
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03519971
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 9, 2018
Start date
Mar 29, 2018
Primary completion
Sep 7, 2023
Completion
Mar 9, 2026
Results posted
Jan 7, 2025
Last update
Jul 14, 2026

Study contacts

Jeffrey Bradley, MD
principal investigator · AstraZeneca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion